CBSA Convenes Experts + Advocates to Discuss the Promise of Genomic Medicine

This week CBSA partnered with the Colorado Cancer Caucus and the Biotechnology innovation Organization (BIO) to host a discussion on the promise of genomic medicine for oncology and rare, genetic diseases. Over 70 people attended the virtual event, including state legislators, patient organizations, academic and research institutions, and life sciences companies.

During the webinar, leading researchers and clinicians in Colorado explained how they are harnessing genomics to diagnose and treat the underlying cause of human disease. Dr. M. Eric Kohler, Assistant Professor at University of Colorado Anschutz and practicing physician at Children’s Hospital Colorado, presented on how he and other physician researchers are targeting cancer cells through novel approaches like CAR-T. Dr. Susan Apkon at Children’s Hospital Colorado provided an overview of the latest advancements in gene therapy and shared her own experiences with how these therapies are being used to treat rare, genetic diseases that, until now, had no treatments.

The panel also featured powerful patient and caregiver stories about their experiences with cancer and rare, genetic disorders and the impact gene and cell therapies could have on the way we treat patients with these diseases.

CBSA is proud how our life sciences community is leading in the field of genomic medicine. These transformative treatments represent a major leap forward in medicine, changing our ability to diagnose, treat and potentially cure many different illnesses.

We look forward to partnering with the General Assembly and other policymakers to support this promising research and development and to explore innovative approaches to provide access for patients.

Categories: CBSA News